

Jeffrey A Bogart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/314600/publications.pdf>

Version: 2024-02-01

61
papers

3,904
citations

430442

18
h-index

174990

52
g-index

61
all docs

61
docs citations

61
times ranked

4350
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 661-670.	0.8	38
2	Systemic Cancer Therapy Does Not Significantly Impact Early Vaccine-Elicited SARS-CoV-2 Immunity in Patients with Solid Tumors. <i>Vaccines</i> , 2022, 10, 738.	2.1	2
3	Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8504-8504.	0.8	2
4	CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7507-7507.	0.8	7
5	Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8505-8505.	0.8	29
6	Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. <i>Lung Cancer</i> , 2021, 156, 68-71.	0.9	8
7	Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 159, 56-65.	0.9	7
8	A Principal Component of Quality-of-Life Measures Is Associated with Survival: Validation in a Prospective Cohort of Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy. <i>Cancers</i> , 2021, 13, 4542.	1.7	6
9	Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. <i>Cancers</i> , 2021, 13, 6193.	1.7	39
10	Heterogeneous Versus Homogeneous Radiation Dose Calculations of Twice-Daily Fractionation in Small Cell Lung Carcinoma. <i>Cureus</i> , 2021, 13, e20226.	0.2	0
11	Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. <i>Practical Radiation Oncology</i> , 2020, 10, 186-194.	1.1	13
12	Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617. <i>Clinical Cancer Research</i> , 2020, 26, 4643-4650.	3.2	47
13	Evaluation of radiation treatment volumes for unknown primaries of the head and neck in the era of FDG PET. <i>PLoS ONE</i> , 2020, 15, e0231042.	1.1	4
14	Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2020, 10, 158-173.	1.1	111
15	A biologically effective dose threshold for stereotactic body radiation therapy“ can we put the issue to BED?. <i>Annals of Translational Medicine</i> , 2020, 8, 1533-1533.	0.7	1
16	Title is missing!. , 2020, 15, e0231042.		0
17	Title is missing!. , 2020, 15, e0231042.		0
18	Title is missing!. , 2020, 15, e0231042.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0231042.		0
20	Title is missing!. , 2020, 15, e0231042.		0
21	One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2019, 105, 752-759.	0.4	85
22	Management of the Brain in Small Cell Lung Cancer: Are Patients Paying a Lot Now Instead of a Little Later?. Journal of Thoracic Oncology, 2019, 14, 153-156.	0.5	0
23	<p>Efficacy and tolerability of stereotactic body radiotherapy for lung metastases in three patients with pediatric malignancies</p>. OncoTargets and Therapy, 2019, Volume 12, 3723-3727.	1.0	10
24	Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?. JAMA Oncology, 2019, 5, 1229.	3.4	0
25	<p>Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 151-159.	1.3	4
26	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood, 2019, 133, 1548-1559.	0.6	292
27	Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14-360/AFT-07).. Journal of Clinical Oncology, 2019, 37, 8510-8510.	0.8	5
28	Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). International Journal of Radiation Oncology Biology Physics, 2018, 101, 177-185.	0.4	35
29	Clinical outcomes following advanced respiratory motion management (respiratory gating or Tj ETQq1 1 0.784314 rgBT /Overlock 10 T cancer. Lung Cancer: Targets and Therapy, 2018, Volume 9, 103-110.	1.3	5
30	The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols. International Journal of Radiation Oncology Biology Physics, 2018, 102, 775-782.	0.4	4
31	Characterization of 1,233 NSCLCs with non-del19/L858R <i>EGFR</i> mutations (<i>EGFR</i>m) using comprehensive genomic profiling (CGP).. Journal of Clinical Oncology, 2018, 36, 9040-9040.	0.8	3
32	Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-“Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. Journal of Clinical Oncology, 2017, 35, 56-62.	0.8	557
33	Management of Patients With Stage I Lung Cancer. Journal of Oncology Practice, 2017, 13, 69-76.	2.5	10
34	Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P): Based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 8546-8546.	0.8	1
35	Evaluation of sexual function on a randomized trial of a prostate rectal spacer.. Journal of Clinical Oncology, 2017, 35, 69-69.	0.8	2
36	Stereotactic Body Radiation Therapy for Stage I Non-“Small Cell Lung Cancer. Thoracic Surgery Clinics, 2016, 26, 261-269.	0.4	12

#	ARTICLE	IF	CITATIONS
37	Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor–Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 500-506.e2.	1.1	21
38	Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. <i>Practical Radiation Oncology</i> , 2015, 5, 149-155.	1.1	78
39	Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 187-199.	5.1	1,625
40	Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. <i>Practical Radiation Oncology</i> , 2015, 5, 141-148.	1.1	79
41	Limited-Stage Small-Cell Lung Cancer: An Age Limit for Combined Modality Therapy?. <i>Journal of Clinical Oncology</i> , 2015, 33, 4235-4237.	0.8	1
42	Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 971-977.	0.4	285
43	Complications From Computed Tomography–Guided Core Needle Biopsy for Patients Receiving Stereotactic Body Radiation Therapy for Early-Stage Lesions of the Lung. <i>Clinical Lung Cancer</i> , 2014, 15, 302-306.	1.1	5
44	Immunotherapy in non-small-cell lung cancer: a good start?. <i>Lancet Oncology</i> , The, 2014, 15, 5-6.	5.1	3
45	A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7501-7501.	0.8	78
46	Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: A randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7506-7506.	0.8	2
47	A phase II study of radiation therapy (RT), paclitaxel poliglumex (PPX), and cetuximab (C) in locally advanced head and neck cancer (LA-HNC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6059-6059.	0.8	0
48	A phase I/II study of radiation therapy, paclitaxel poliglumex, and cetuximab in locally advanced head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e16047-e16047.	0.8	1
49	Tolerability of and biochemical control of permanent Pd-103 brachytherapy followed by external beam radiotherapy for localized prostate adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 245-245.	0.8	1
50	Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904. <i>Journal of Clinical Oncology</i> , 2010, 28, 202-206.	0.8	74
51	Fractionated Radiotherapy for High-Risk Patients with Early-Stage Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2010, 22, 44-52.	0.4	6
52	Rationale for Phase III Trials of Thoracic Radiation Therapy Doses in Limited-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, 202-205.	1.1	8
53	Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235. <i>Lung Cancer</i> , 2008, 62, 92-98.	0.9	10
54	Stereotactic Body Radiotherapy for Poor-Risk Lung Cancer: “More Cyber, Less Knife”. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 75-77.	1.0	2

#	ARTICLE	IF	CITATIONS
55	A Randomized Phase II Study of Radiation Therapy, Pemetrexed, and Carboplatin with or Without Cetuximab in Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2006, 7, 285-287.	1.1	16
56	Radiation Oncology Research in the Cancer and Leukemia Group B: Table 1.. <i>Clinical Cancer Research</i> , 2006, 12, 3628s-3634s.	3.2	1
57	Dose-Intensive Thoracic Radiation Therapy for Patients at High Risk with Early-Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 6, 350-354.	1.1	9
58	Localized Non-Small Cell Lung Cancer: Adjuvant Radiotherapy in the Era of Effective Systemic Therapy. <i>Clinical Cancer Research</i> , 2005, 11, 5004s-5010s.	3.2	42
59	70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 460-468.	0.4	164
60	Early stage medically inoperable non-small cell lung cancer. <i>Current Treatment Options in Oncology</i> , 2003, 4, 81-88.	1.3	10
61	Resection and permanent I-125 brachytherapy without whole brain irradiation for solitary brain metastasis from non-small cell lung carcinoma. <i>Journal of Neuro-Oncology</i> , 1999, 44, 53-57.	1.4	44